Atlanta, GANCT05549297Now EnrollingIRB Ready

Melanoma Clinical Trial in Atlanta, GA

Access cutting-edge melanoma treatment through this phase 3 clinical trial at a research site in Atlanta. Study-provided care at no cost to qualified participants.

Sponsored by Immunocore Ltd

Quick Self-Assessment

See if you qualify for this Atlanta location

Preparing your pre-screening questions…

Expert Care in Atlanta

Access melanoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related melanoma treatment provided free

Apply for This Atlanta Location

Check if you qualify for this melanoma clinical trial in Atlanta, GA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Atlanta

    Convenient for GA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Atlanta site if eligible
  4. 4Begin participation

About This Melanoma Study in Atlanta

The purpose of this study is to evaluate the efficacy and safety of tebentafusp-based regimens, including tebentafusp monotherapy and in combination with anti-PD1 vs investigator choice (including clinical trials of investigational agents, salvage therapy per local standard of care \[SoC\], best supportive care \[BSC\] on protocol survivor follow up) in patients with advanced non-ocular melanoma.

Sponsor: Immunocore Ltd

Who Can Participate

Inclusion Criteria

HLA-A\*02:01-positive
unresectable Stage III or Stage IV non-ocular melanoma
archival tumor tissue sample or a newly obtained biopsy of a tumor lesion not previously irradiated has been provided.
measurable or non-measurable disease per RECIST 1.1
Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
If applicable, must agree to use highly effective contraception
Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the Informed Consent (ICF) and protocol
Must agree to provide protocol specified samples for biomarker analyses.

Exclusion Criteria

Pregnant or lactating women
diagnosis of ocular or metastatic uveal melanoma
history of a malignant disease other than those being treated in this study
ineligible to be retreated with pembrolizumab due to a treatment-related AE
known untreated or symptomatic central nervous system (CNS) metastases and/or carcinomatous meningitis
previous severe hypersensitivity reaction to treatment with another monoclonal antibody (mAb)
active autoimmune disease requiring immunosuppressive treatment
known psychiatric or substance abuse disorders
received prior treatment with a licensed or investigative Immune-mobilizing monoclonal T-cell receptor Against Cancer (ImmTAC) medication or who have not completed adequate washout from prior medications.
received chemotherapy or biological cancer therapy (excluding anti-PD(L)1 mAb, ipilimumab, and BRAF TKI regimen) within 14 days of first dose
received cellular therapies within 90 days of study intervention
ongoing Common Terminology Criteria for Adverse Events(CTCAE) Grade ≥ 2 clinically significant who in the opinion of the investigator could affect the outcome of the study
received systemic treatment with steroids or any other immunosuppressive drug within 2 weeks of first dose
have not progressed on treatment with an anti-PD(L)1 mAb
have not received prior treatment with an approved anti-CTLA-4 mAb
have a BRAF V600 mutation, who have not received a prior BRAF/MEK TKI regimen
currently participating or have participated in a study of an investigational agent or using an investigational device within 30 days of the first dose
known history of chronic viral infections such as hepatitis B virus (HBV) or hepatitis C virus (HCV)
known clinically significant pulmonary or cardiac disease or impaired lung or cardiac function
Out of range Laboratory values
history of allogenic tissue/solid organ transplant

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Atlanta?

Yes, this clinical trial (NCT05549297) has an active research site in Atlanta, GA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Melanoma Treatment Options in Atlanta, GA

If you're searching for melanoma treatment options in Atlanta, GA, this clinical trial (NCT05549297) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Atlanta research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced melanoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all melanoma clinical trials near you to find additional studies recruiting in your area.

More Melanoma Trials in Atlanta, GA

See all melanoma clinical trials recruiting in Atlanta — not just this study.

Browse Melanoma Trials in Atlanta →

Browse More Trials by Condition

Melanoma TrialsBasal Cell Carcinoma TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Atlanta?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Atlanta, GA